Drug Profile
Testosterone intranasal - Acerus Pharmaceuticals Corporation
Alternative Names: CompleoTRT™; MPP 10; Nasobol; NATESTO; TBS-1Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Mattern Pharmaceuticals
- Developer Acerus Pharmaceuticals; Aytu BioPharma; Hyundai Pharmaceutical; Medac
- Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Androgen receptor agonists; Growth stimulants; Testosterone congener stimulants; Testosterone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypogonadism
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Hypogonadism(In adolescents) in United Kingdom (Intranasal, Gel)
- 15 Sep 2022 Launched for Hypogonadism in Canada (Intranasal)
- 14 Jan 2022 Acerus Pharmaceuticals entered into a marketing agreement with Verity Pharmaceuticals for the exclusive rights to promote NATESTO in Puerto Rico